Does switching anti-TNF alpha biologic agents represent an effective option in childhood chronic uveitis

The evidence from a systematic review and meta-analysis approach

Gabriele Simonini*, Katie Druce, Rolando Cimaz, Gary J. Macfarlane, Gareth T. Jones

*Corresponding author for this work

Research output: Contribution to journalLiterature review

13 Citations (Scopus)

Abstract

Objective: To summarize the evidence regarding the effectiveness of switching to a second anti-TNF alpha treatment in children with autoimmune chronic uveitis (ACU), refractory to the first course of anti-TNF alpha treatment.

Methods: We conducted a systematic literature review between January 2000 and May 2013 to investigate the efficacy of a second anti-TNF alpha agent in the treatment of ACU in children (

Results: Among 1086 identified articles, 128 were scrutinized: 10 observational studies, 6 on adalimumab (ADA), 3 on infliximab (INF), and 1 on both, were deemed eligible. Study cohort included 40 children (ADA = 34 and INF = 6), median age 8 years (range 3-16). Nine were males, 28 females (gender not reported in 3), 39/40 were affected by JIA Seventeen children received etanercept: 11 were switched to ADA, the remaining 6 to INF. All 23 children who previously received INF were switched to ADA. Altogether, 30 children (24 on ADA, 6 on INF) of 40 responded to treatment: 0.75 (95% CI: 0.51-100) was the combined estimate of the proportion of subjects improving.

Conclusions: Despite the fact that no RCT is available and the number of cases is small, this review provides evidence that switching to a second anti-TNF alpha agent results in improvement of ocular activity for the 75% treated children (C) 2014 Elsevier Inc. All rights reserved.

Original languageEnglish
Pages (from-to)39-46
Number of pages8
JournalSeminars in arthritis and rheumatism
Volume44
Issue number1
Early online date6 Mar 2014
DOIs
Publication statusPublished - Aug 2014

Keywords

  • Adalimumab
  • Infliximab
  • Etanercept
  • Autoimmune chronic uveitis
  • Childhood
  • Refractory uveitis
  • Juvenile Idiopathic Arthritis
  • Efficacy
  • Children
  • Therapy
  • Safety

Cite this

@article{986cbea92c734af5a591ada9f6188381,
title = "Does switching anti-TNF alpha biologic agents represent an effective option in childhood chronic uveitis: The evidence from a systematic review and meta-analysis approach",
abstract = "Objective: To summarize the evidence regarding the effectiveness of switching to a second anti-TNF alpha treatment in children with autoimmune chronic uveitis (ACU), refractory to the first course of anti-TNF alpha treatment.Methods: We conducted a systematic literature review between January 2000 and May 2013 to investigate the efficacy of a second anti-TNF alpha agent in the treatment of ACU in children (Results: Among 1086 identified articles, 128 were scrutinized: 10 observational studies, 6 on adalimumab (ADA), 3 on infliximab (INF), and 1 on both, were deemed eligible. Study cohort included 40 children (ADA = 34 and INF = 6), median age 8 years (range 3-16). Nine were males, 28 females (gender not reported in 3), 39/40 were affected by JIA Seventeen children received etanercept: 11 were switched to ADA, the remaining 6 to INF. All 23 children who previously received INF were switched to ADA. Altogether, 30 children (24 on ADA, 6 on INF) of 40 responded to treatment: 0.75 (95{\%} CI: 0.51-100) was the combined estimate of the proportion of subjects improving.Conclusions: Despite the fact that no RCT is available and the number of cases is small, this review provides evidence that switching to a second anti-TNF alpha agent results in improvement of ocular activity for the 75{\%} treated children (C) 2014 Elsevier Inc. All rights reserved.",
keywords = "Adalimumab, Infliximab, Etanercept, Autoimmune chronic uveitis, Childhood, Refractory uveitis, Juvenile Idiopathic Arthritis, Efficacy, Children, Therapy, Safety",
author = "Gabriele Simonini and Katie Druce and Rolando Cimaz and Macfarlane, {Gary J.} and Jones, {Gareth T.}",
year = "2014",
month = "8",
doi = "10.1016/j.semarthrit.2014.03.001",
language = "English",
volume = "44",
pages = "39--46",
journal = "Seminars in arthritis and rheumatism",
issn = "0049-0172",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Does switching anti-TNF alpha biologic agents represent an effective option in childhood chronic uveitis

T2 - The evidence from a systematic review and meta-analysis approach

AU - Simonini, Gabriele

AU - Druce, Katie

AU - Cimaz, Rolando

AU - Macfarlane, Gary J.

AU - Jones, Gareth T.

PY - 2014/8

Y1 - 2014/8

N2 - Objective: To summarize the evidence regarding the effectiveness of switching to a second anti-TNF alpha treatment in children with autoimmune chronic uveitis (ACU), refractory to the first course of anti-TNF alpha treatment.Methods: We conducted a systematic literature review between January 2000 and May 2013 to investigate the efficacy of a second anti-TNF alpha agent in the treatment of ACU in children (Results: Among 1086 identified articles, 128 were scrutinized: 10 observational studies, 6 on adalimumab (ADA), 3 on infliximab (INF), and 1 on both, were deemed eligible. Study cohort included 40 children (ADA = 34 and INF = 6), median age 8 years (range 3-16). Nine were males, 28 females (gender not reported in 3), 39/40 were affected by JIA Seventeen children received etanercept: 11 were switched to ADA, the remaining 6 to INF. All 23 children who previously received INF were switched to ADA. Altogether, 30 children (24 on ADA, 6 on INF) of 40 responded to treatment: 0.75 (95% CI: 0.51-100) was the combined estimate of the proportion of subjects improving.Conclusions: Despite the fact that no RCT is available and the number of cases is small, this review provides evidence that switching to a second anti-TNF alpha agent results in improvement of ocular activity for the 75% treated children (C) 2014 Elsevier Inc. All rights reserved.

AB - Objective: To summarize the evidence regarding the effectiveness of switching to a second anti-TNF alpha treatment in children with autoimmune chronic uveitis (ACU), refractory to the first course of anti-TNF alpha treatment.Methods: We conducted a systematic literature review between January 2000 and May 2013 to investigate the efficacy of a second anti-TNF alpha agent in the treatment of ACU in children (Results: Among 1086 identified articles, 128 were scrutinized: 10 observational studies, 6 on adalimumab (ADA), 3 on infliximab (INF), and 1 on both, were deemed eligible. Study cohort included 40 children (ADA = 34 and INF = 6), median age 8 years (range 3-16). Nine were males, 28 females (gender not reported in 3), 39/40 were affected by JIA Seventeen children received etanercept: 11 were switched to ADA, the remaining 6 to INF. All 23 children who previously received INF were switched to ADA. Altogether, 30 children (24 on ADA, 6 on INF) of 40 responded to treatment: 0.75 (95% CI: 0.51-100) was the combined estimate of the proportion of subjects improving.Conclusions: Despite the fact that no RCT is available and the number of cases is small, this review provides evidence that switching to a second anti-TNF alpha agent results in improvement of ocular activity for the 75% treated children (C) 2014 Elsevier Inc. All rights reserved.

KW - Adalimumab

KW - Infliximab

KW - Etanercept

KW - Autoimmune chronic uveitis

KW - Childhood

KW - Refractory uveitis

KW - Juvenile Idiopathic Arthritis

KW - Efficacy

KW - Children

KW - Therapy

KW - Safety

U2 - 10.1016/j.semarthrit.2014.03.001

DO - 10.1016/j.semarthrit.2014.03.001

M3 - Literature review

VL - 44

SP - 39

EP - 46

JO - Seminars in arthritis and rheumatism

JF - Seminars in arthritis and rheumatism

SN - 0049-0172

IS - 1

ER -